Mymd Pharmaceuticals (NASDAQ:QCLS – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.19) EPS for the quarter, Zacks reports.
Mymd Pharmaceuticals Trading Down 15.6%
NASDAQ QCLS traded down $0.80 during trading on Friday, hitting $4.33. 612,859 shares of the company’s stock were exchanged, compared to its average volume of 571,102. The company has a market cap of $18.06 million, a price-to-earnings ratio of -0.04 and a beta of 2.11. Mymd Pharmaceuticals has a fifty-two week low of $2.50 and a fifty-two week high of $33.56.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings started coverage on Mymd Pharmaceuticals in a research note on Wednesday. They issued a “sell (e+)” rating for the company. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Mymd Pharmaceuticals has a consensus rating of “Sell”.
Mymd Pharmaceuticals Company Profile
MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.
The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.
See Also
- Five stocks we like better than Mymd Pharmaceuticals
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Mymd Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mymd Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
